

Challenging paradigms in lymphoma treatment

M. Bendandi^{1*†}, S. A. Pileri² & P. L. Zinzani³

¹Department of Hematology and Cell Therapy Area, University Clinic, University of Navarra, Pamplona, Spain; ²Chair of Pathologic Anatomy & Unit of Haematopathology and ³Lymphoma Unit, Institute of Haematology and Clinical Oncology 'L. & A. Seràgnoli', Bologna University, Bologna, Italy

Received 30 April 2003; revised 23 September 2003; accepted 16 December 2003

Key words: lymphoma classification, lymphoma treatment

Introduction

Among the several merits that must be ascribed to the Revised European–American Lymphoma (REAL) classification [1], the most relevant from a therapeutic standpoint is that it has ultimately allowed clinicians all over the world to fully compare the results of clinical trials conducted elsewhere. Therefore, it is not surprising that it was included almost untouched within the current WHO classification of Tumours of Haematopoietic and Lymphoid Tissues [2]. All previous lymphoma classifications had failed in this scope, mainly owing to the different language and concepts used by pathologists and clinicians in different countries to refer to the variegated panorama of lymphoid tumors.

Meanwhile, the continuous effort towards the refinement of lymphoma patients' prognosis systems has also succeeded in elaborating new and better prognostic indexes, such as the International Prognosis Index (IPI) [3] and, perhaps, the more recent Follicular Lymphoma International Prognostic Index (FLIPI) [4]. It is indeed expected that the better categorization of patients, which is intrinsic to the systematic and broad use of these scores, will help to reach higher overall cure rates by calibrating disease treatment to the real needs of the individual patient. In this respect, the concomitant effort to objectively combine 'traditional', biological and clinical prognostic factors with the astonishingly attractive findings of lymphoma genome profiling [5, 6] seems to represent another crucial step towards improving the process of selecting the best possible treatment. Of course, this ongoing effort might even confuse the whole scenario of lymphoma management in the short-term, but the ultimate hope is that it will prove invaluable in clarifying a number of concepts. Among them for instance, in a time of rapidly aging population, the concept of the 'elderly patient' is still too vague, undefined and often neglected.

Over the last two decades, it has become increasingly clear that intensified treatment does not necessarily translate into better clinical results. In particular, the unique goal to be pursued should

remain that of curing as many patients as possible with as little treatment as possible. However, this lesson has apparently only been applied dose- and field extension-wise to radiation treatment (RT), whereas the same attention has not always been given to chemotherapy (CHT) dose intensity reduction. This fact, aside from the obvious issue of short- and long-term toxicity in general, has generated paradoxical situations such as that of Hodgkin's disease (HD) and follicular lymphoma (FL). In the case of the highly curable HD, aggressive CHT regimens [7–9] have erased the significance of any prognostic factor at diagnosis [10, 11], while increasing both the overall toxicity and the second neoplasm frequency, without abolishing in principle the risk of progression, resistance or relapse. The only logical conclusion that can be drawn from these facts is that, currently, an important fraction of HD patients may be overtreated [12]. On the other hand, in the case of the substantially incurable FL, the number of treatment options and the tendency towards chemotherapy intensification [13–17] have led to a confusing situation where a number of patients are also possibly either over or poorly treated, without a clear-cut improvement in either cure or survival rates.

An important area of both new hope and concern is the growing number of biological therapies that have come into their own. Among them, passive, active, adoptive and radio-immunotherapy share great promise and raise important questions in terms of appropriateness of their clinical use. It will be advisable to study carefully their effective applications to lymphoma treatment, in order to possibly avoid the unfortunate experience with α -interferon, which paradoxically is still used in individual patients, but is kept out of most clinical trials.

All in all, both the recent and the expected further findings in lymphoma classification, prognostic systems and treatment options justify being optimistic of a substantial improvement of the already relatively satisfactory results achieved in lymphoma management.

Hodgkin's disease

Currently, the major management issues related to HD concern the treatment options for patients presenting with the following: stage IA, stage IB and II, stage III and IV, elderly age, residual mediastinal lesions, and relapse or resistance. In addition, nearly

*Correspondence to: Dr M. Bendandi, Department of Hematology and Cell Therapy Area, University Clinic, University of Navarra, Avda. Pio XII, 36–31008 Pamplona, Spain. Tel: +34-948-255-400 ext. 2456; Fax: +34-948-296-500; E-mail: mbendandi@unav.es
†Leukemia and Lymphoma Society Scholar in Clinical Research.

half a century after the first HD cases were cured by RT alone, the exact role of this treatment option is now, more than ever, under intense scrutiny.

Over the last couple of years, at least four studies have been conducted and published, while others have been started, in order to possibly contribute to the clarification of the way a patient should be treated at diagnosis, mainly depending on the Ann Arbor stage only.

Press et al. [18] have randomized as many as 348 patients with either IA or IIA, supradiaphragmatic HD to receive either subtotal lymphoid irradiation (STLI) or three cycles of doxorubicin- and vinblastine-based CHT plus STLI. Response-wise, the latter treatment option proved dramatically superior in terms of both failure-free survival (94% versus 81%) and relapse rate ($P < 0.001$). However, the relatively short follow-up time (3.3 years) does not allow a complete assessment of other parameters, such as overall survival (OS) and long-term toxicity.

In Germany, Sieber et al. [19] randomized 996 patients with stage I–III disease (excluding those in stage I–II with no risk factors) to receive, in combination with extended-field RT, either rapidly alternating COPP/ABV/IMEP or conventional alternating COPP/ABVD. With a median follow-up time of 7 years, no differences at all were found in terms of complete responses (CR = 94% versus 93%, respectively), freedom from treatment failure (79% versus 80%, respectively), OS (88% in both arms) and second neoplasm frequency (22 events in both arms), or serious infections and toxic deaths.

Horning et al. [8] recently updated the results of their prospective clinical trial on the use of Stanford V CHT regimen plus RT (on bulky sites only) for HD patients with either stage I–II with bulky mediastinal mass presentation or stage III–IV. With a median follow-up of 5.4 years, the 5-year freedom from progression (FFP) was 89% and the OS was 96%, with a highly significant difference in terms of FFP for the patients with prognostic score [10] < 3 (94% versus 75%, respectively; $P < 0.0001$). Considering also that no secondary leukemia has occurred yet, as many as 46 pregnancies have been recorded instead ever since and the freedom from second relapse for the 16 relapsed patients was 69%, high expectations suggest the ongoing Intergroup trial (E2496) randomizing HD patients should receive either standard ABVD or Stanford V (both with and without RT).

In fact, a recent preliminary report, characterized by an unexpectedly low response rate of HD patients to the Stanford V regimen, is further confusing the scenario. Levis et al. [20] randomized 355 advanced stage (IIB–IV) HD patients to receive standard ABVD, Stanford V or MOPP/EBV/CAD (MEC), each followed by RT on residual and/or bulky disease sites. At the most recent interim evaluation, as many as 272 patients were evaluable (ABVD = 98; MEC = 83; Stanford V = 91), and the main clinical features were well balanced among the three groups. The CR rates (CR + unconfirmed CR) were 70%, 71% and 58%, respectively, prior to RT and 89%, 92% and 73%, respectively, following RT completion. In both cases, ABVD and MEC showed better results ($P < 0.01$) than Stanford V. Furthermore, MEC proved significantly more toxic than the other two CHT regimens.

Finally, Radford et al. [21] randomized 282 HD patients either in stage I–II (with bulky mediastinal presentation and/or B symptoms) or III–IV to receive either ChlVPP/EVA or VAPEC-B (both followed by RT on residual and/or bulky disease sites). With a median follow-up time of 4.9 years, the superiority of the former CHT regimen has been rapidly and clearly demonstrated in terms of 5-year FFP (82% versus 62%, respectively), event-free survival (EFS = 78% versus 58%, respectively) and OS (89% versus 79%, respectively). However, it appears that, in the subset of patients with prognostic score < 3 , the two regimens are equivalent.

All in all, these data seem to once again point out that when treating HD patients, a little more attention should be paid at diagnosis to their prognostic factors than only to the highest CR rates achieved by each CHT regimen. Otherwise, the risk of paying too high a global price for overtreatment appears to be excessive. In addition, the same concept should be applied to limiting the use of adjuvant RT in both early and advanced stage HD [12].

In general, it is far from unreasonable to treat HD patients presenting in stage IA without unfavorable prognostic factors with RT alone. Likewise, patients presenting with stage IB–II disease may be well treated with ABVD plus RT on residual and/or bulky disease sites only. On the other hand, the quest for the best possible treatment for HD patients presenting with stage III–IV disease is far from over. Save the BEACOPP [7] regimen, which is however characterized by higher short- and long-term toxicity [22], no other CHT schema has yet proved to be superior to the ABVD regimen. Therefore, other randomized trials such as the above-mentioned E2496 are warranted.

As for the treatment of elderly patients with HD, the lack of clear-cut data from randomized trials, as well as the difficulty in establishing a common ground about the age limit past which a patient should be considered elderly, mean that each group's experience ends up having some, but not much, scientific merit. In our experience, the VBM regimen [23], eventually followed by RT on residual and/or bulky disease sites, is reliable and relatively efficacious for HD patients above the age of 65 years.

The diagnostic management of residual mediastinal lesions following HD treatment has recently been revolutionized by the advent of [18 F]fluorodeoxyglucose positron emission tomography (FDG PET). The very few [24] or even absent (our unpublished data) cases of false-negative FDG PET reported, together with the equally lower and lower number of false-positives [24] and the greater experience being gained by FDG PET specialists, are setting the stage for whole-body FDG PET to become a fundamental tool in HD patient management. In particular, its role in association with computed tomography scans seems to be pivotal in the restaging of patients with mediastinum and abdomen bulky disease presentation. In this setting, that is following CHT with or without RT, its specific ability to both analyze residual masses and discriminate between active disease and fibrosis/sclerosis ends up being prognostically decisive in most, if not all, cases. This concept is very important in the decision-making process, which may or may not include further treatment for patients with disease persistence after the induction phase. In addition, FDG PET could prove to be an early imaging predictive factor allowing stratifi-

cation of responding and non-responding patients after few courses of chemotherapy [25]. However, it is clear that whenever FDG PET is felt to potentially increase HD patient management quality, it should be performed at diagnosis as well, in order to allow clear-cut comparisons with those carried out at the time of restaging/follow-up.

Concerning RT, its role in advanced stage HD patients seems to be irrelevant in terms of OS and relapse-free survival (RFS), as shown by a recent European Organisation for Research and Treatment of Cancer study [26]. In this trial, a first detailed analysis showed that involved-field RT (IF-RT) did not improve RFS and OS in patients who had already achieved a CR with the MOPP/ABV regimen. Remarkably, though, those patients who had obtained a partial response (PR) and were subsequently treated with additional IF-RT had comparable overall outcome to those who had reached a CR. Once again, these data would suggest that, save for stage IA HD patients, RT might be reserved to all cases either presenting with bulky disease at diagnosis or achieving a PR following first-line CHT.

Finally, relapsing, resistant and primary progressive HD patients still pose one of the most serious challenges to the hematology/oncology scientific community [9]. According to recent data from the German Hodgkin's Lymphoma Study Group, primary progressive HD patients >50 years old, who have both a poor Karnofsky performance score and fail to attain a temporary remission on first-line treatment, have an extremely poor prognosis and should be considered for high-dose CHT (HDCT) followed by autologous stem-cell transplantation (ASCT) [27]. The same group also reports that similar conclusions should be drawn for early relapsing HD patients, particularly those who present with advanced disease and anemia at the time of relapse [28].

It is clear that, in all poor-prognosis HD patients, the only current hope for cure remains based on the possible success of HDCT followed by either ASCT [29] and/or non-myeloablative, reduced-conditioning, allogeneic SCT [16, 17]. In fact, in contrast to non-Hodgkin's lymphoma (NHL), the possible impact of novel treatment modalities including new drugs, immunotherapy and radio-immunotherapy appears not yet to be in the making.

Diffuse large B-cell lymphoma

Over the last decade, the first and foremost problem associated with the management of diffuse large B-cell lymphoma (DLBCL) has been how to move on from the shocking results of two randomized studies conducted by Fisher and colleagues. These trials proved that, for the treatment of aggressive NHL, third-generation CHT regimens were not statistically superior to CHOP [30], and that three cycles of CHOP were statistically superior to eight, provided that these three cycles of CHT were followed by IF-RT [31]. Ever since, a number of trials have been conducted either to attempt to refute these data, by also comparing standard CHOP with other treatment options, or as though these data did not exist at all, by either exploring therapeutic approaches other than CHOP or integrating CHOP with other therapeutic agents such as anti-CD20 monoclonal antibodies (R-CHOP). Regarding localized DLBCL, Fillet et al. [32] compared four cycles of CHOP with four

cycles of CHOP followed by IF-RT. In that study, 455 patients were randomized to receive each treatment option, and 5-year EFS and OS were not different. The authors concluded that IF-RT following four cycles of CHOP added no benefit. Meanwhile, an update of the Southwest Oncology Group experience [31] with a follow-up in excess of 8 years now shows that PFS and OS curves have merged at 7 and 9 years, respectively [33].

As far as the combination of CHOP with passive immunotherapy is concerned, Vose et al. [34] first showed that the addition of rituximab to standard CHOP neither worsened CHT efficacy nor added any toxicity supplement to aggressive NHL patients. Even more compelling evidence in favor of this association was then provided by Coiffier et al. [35] in the elderly, in this case >60 years old, aggressive NHL patients. In particular, with a follow-up of 2 years, they found that in a randomized setting, the addition of rituximab to CHOP increased the CR rate from 63% to 76% ($P = 0.005$), the EFS from 39% to 57% ($P < 0.001$) and the OS from 57% to 70% ($P = 0.007$). Whether the further addition of rituximab alone as a maintenance treatment may exert a substantial clinical effect in this as well as in many other lymphoma settings is one of the most urgent questions that needs to be answered through randomized, controlled, phase III clinical trials.

On the other hand, and again in aggressive NHL patients >60 years old, Mainwaring et al. [36] surprisingly reported somewhat better results using a CHT regimen including mitoxantrone rather than doxorubicin. In a BNLI-sponsored, randomized trial comparing PAadriaCEBO with PMitCEBO, and with a 4-year follow-up, the latter appeared to be superior in terms of overall response (OR) rate (78% versus 69%; $P = 0.05$) and OS (50% versus 28%; $P = 0.0067$), but not in terms of CR rate and RFS.

In the substantial absence of a consensus CHT regimen accepted worldwide to treat aggressive NHL in general, and DLBCL in particular, at diagnosis, more effort appears to have been placed in possibly identifying DLBCL subtypes characterized by important prognostic differences. For instance, Wilder et al. [37] prospectively confirmed that, at diagnosis, doxorubicin-based CHT with or without IF-RT can be considered an acceptable option only for DLBCL patients with an IPI score <3. Meanwhile, Wilson et al. [38] have suggested that dose-adjusted EPOCH seems to kill DLBCL cells more effectively than a CHOP-based regimen, and this fact might prove quite important, particularly in the light of the possible identification of DLBCL subsets characterized by poorer prognosis, such as bcl-2-positive [39] and CD5-positive [40] DLBCL.

In the last few years, DLBCL has aroused a great deal of interest among researchers, becoming a model for all studies on malignant lymphomas. Its prevalence has facilitated the collection of large series of cases for the application of novel and sophisticated techniques, such as gene expression profiling and tissue microarrays. These techniques have confirmed the heterogeneity of the process, which had already been envisaged through cell morphology. However, converse to the latter, they have provided for the first time criteria for useful DLBCL subclassification, allowing the possible identification of subgroups of patients with different prognoses and different responses to the therapies already available. In addition, they have made feasible the understanding of the

molecular alterations that may be at work in each individual patient. This fact is likely to bring much closer the final goal of developing new drugs and tailored strategies capable of selectively blocking the aberrant pathways involved in the initiation, development and progression of the tumor [41].

Regarding the imaging field, PET scanning is a promising method for identifying patients that, after induction treatment, can or cannot be considered to be in CR. Thus, PET has to be considered an important technique for tailoring the specific treatment depending on the presence or absence of residual disease. In particular, most PET-positive patients at the end of the induction treatment relapse within the first 2 years [42]. In addition, early assessment with PET scan in patients with untreated aggressive NHLs may play a role in predicting the ultimate patient outcome [43].

Finally, as far as poor-prognosis, relapsed, resistant or progressive DLBCL patients are concerned, while waiting for radio-immunotherapy [44] to possibly exert a tangible role, at least for some of them, ASCT remains the favored therapeutic option of most clinicians [45, 46]. In this light, of some interest are the recent data reported by the GELA group on the better outcome of patients receiving CHT with high dose intensity prior to ASCT [47] and those reported by Vose et al. [48] on the lack of prognostic impact by the choice of either peripheral blood or bone marrow as a source for ASCT. In contrast, what seems to matter more is that either source of hematopoietic precursors could be MRD-negative by molecular analysis [48]. *In vivo* purging with rituximab therapy has been shown to be effective in follicular lymphoma patients [49], most of them showing a disappearance of bcl-2-positive cells in the harvest. However, no such marker exists in DLBCL, and the proportion of patients with circulating lymphoma cells is conspicuously lower than in indolent lymphoma. Thus, the interest in this option remains disputable, and no conclusive evidence in its favor has yet been presented.

Although there is consistent evidence for the efficacy of ASCT in patients with CHT-sensitive relapse, the role of transplantation as first-line therapy in PR or CR cases remains uncertain. In particular, previous randomized studies reported by Santini et al. [50] and Haioun et al. [47] suggested that ASCT should be restricted to intermediate-/high-risk and high-risk groups as defined by the IPI. However, we believe that such a hypothesis has to be firmly confirmed in subsequent prospective randomized trials, particularly in the light of other recent data suggesting the need for IPI age adjustment in relapsed and primary refractory DLBCL patients undergoing ASCT [51].

Finally, immunotherapy has begun to gain interest in the setting of DLBCL as well, although the very first preliminary results seem to indicate the need for complex approaches, such as that of combining adoptive transfer of co-stimulated T cells and vaccine strategies in order to possibly achieve clinical efficacy [52].

Mantle cell lymphoma

Nowadays, the only positive feature of mantle cell lymphoma (MCL) remains its relatively low epidemiological incidence [2]. As a matter of fact, from a therapeutic standpoint, most clinical trials raise only slight hopes, and not always, while no real progress has yet been made.

Possibly the most negative evidence emerging recently was reported by Howard et al. [53], who treated 40 newly diagnosed MCL patients with R-CHOP. Their findings seem to indicate that not even the tumor-specific bcl-1/IgH rearrangement disappearance according to qualitative PCR is enough to predict a better outcome in terms of PFS for the MCL patients who achieve it. However, the same concept does not seem to apply when the same modality is used as an *in vivo* purging prior to stem cell collection and ASCT [54], warranting further clinical investigation in this setting. Furthermore, since promising results have recently been observed response-wise with intensive regimens such as hyper-CVAD alone [55] or combined with rituximab [56], it is still possible that the further development of combined modality treatments of this kind may prove reasonably successful in MCL management.

Following a different approach, Lefrere et al. [57], apart from confirming the extremely poor response rate of MCL patients to CHOP alone, have shown that sequential CHT based on the administration of the DHAP regimen to all patients who do not achieve a CR with CHOP allows many more patients to proceed to HDCT in CR. However, the big problem is once again that it is still not clear at all whether HDCT followed by ASCT exerts any impact on the outcome of MCL patients. Perhaps a good way to answer this last question might be to intensify the high-dose conditioning regimen of ASCT by integrating it with a radiolabeled, anti-CD20 monoclonal antibody such as tositumomab. In this respect, the preliminary results recently reported by Gopal et al. [58] of 3-year OS of 91% and PFS of 61% justify a cautious hope.

A review from the European Blood and Marrow Transplant Registry based on the Autologous Blood and Marrow Transplant Registry for patients with MCL transplanted between 1988 and 1998 has recently been published by Vanderberghe et al. [59]. Of 340 patients identified, as many as 195 had analyzable data after record review, including 42 (21%) who had undergone ASCT in first CR. Patients transplanted in first CR had a significantly better outcome than those transplanted in any other remission status. In particular, patients transplanted in first CR featured an OS of 88% at 2 years and 65% at 5 years, as well as a PFS of 65% and 52%, respectively. Early patients, that is >60 years old, fared considerably worse than younger patients. Long-term follow-up is obviously required to both assess the impact of this treatment and to fully evaluate its curative potential [54].

Finally, standard CHT treatment followed by anti-idiotypic (Id) vaccination deserves consideration as another important option for investigation in MCL. According to preliminary data, the most advanced phase II clinical trial, sponsored by the National Cancer Institute (NCI), is indeed showing encouraging and partially unexpected findings [60]. In particular, the addition of rituximab to the EPOCH regimen and the early Id vaccination following CHT completion seems to interfere only partially with the Id vaccine's capability of eliciting specific humoral responses. This fact is very important, because as it is not yet known what is the real therapeutic role played by either the humoral and/or the cellular immune response, until now it was thought that B-cell depletion caused by rituximab might hinder the overall Id vaccine effectiveness [61].

Follicular lymphoma

As nobody yet dares to envision a therapeutic strategy capable of curing an acceptable proportion of FL patients, the current state-of-the-art reflects the tendency to focus such efforts mainly towards four options: conventional CHT, HDCT followed by ASCT, allogeneic SCT and immunotherapy.

As far as conventional CHT is concerned, results remain extremely disappointing, and even the data from Lynch et al. [62] on the impact exerted by an induction combination of fludarabine and interferon- α -2a, followed by maintenance therapy with the latter, seem to confirm this overall impression.

However, not much can yet be said in favor of HDCT followed by ASCT either [63]. In particular, the data from Williams et al. [64], comparing in a case-control fashion the post-ASCT outcome of patients with *de novo* FL, transformed FL and *de novo* aggressive NHL, show no significant differences between the three groups, as well as overall results being far from satisfactory.

On the other hand, allogeneic SCT is mostly considered, as a therapeutic weapon, as intriguing, given the fact that it may possibly cure a patient, and as risky, owing to the considerable high death rate associated with it. The latter is, of course, the main reason for all such trials ending up enrolling a limited number of patients over a generally extended period of time. The study by Forrest et al. [65] is no exception to this trend. Over 8 years, as many as 24 patients with progressive FL underwent conventional conditioning and allogeneic SCT. Five early deaths were recorded, four of which were directly dependent upon the transplant procedure. Meanwhile, with a median follow-up of nearly 2.5 years, no surviving patient has yet relapsed. However, much more compelling appears to be the data from Khouri et al. [66], who with similar features in terms of both short follow-up and a small number of patients, although enrolled over a much shorter period of time, are basically reproducing the same clinical results without experiencing such a critical transplant-related mortality. Since the major difference between the two trials lies in the use of a non-myeloablative, reduced-conditioning regimen in the latter, there is no doubt that this relatively new way to manage FL therapeutically might soon prove decisive.

The field that is currently under more pressure, as far as the quest for a cure for FL is concerned, is that of immunotherapy. It is here that basic and clinical investigations seem to meet almost on a daily basis to close the gap that still exists between our knowledge and the possibility of consistently curing FL patients.

The fact that rituximab alone does not cure FL, but that it can be useful and effective in several FL patients, particularly those with low tumor burden and those for any reasons not immediately undergoing Id vaccine therapy, appears to have been established [60, 67, 68]. Moreover, very interesting results have been also reported on the capability of rituximab, sequentially added to CHOP, to greatly increase the number of previously untreated FL patients achieving a molecular response and, thereby, to improve their RFS [69]. Moreover, Czuczman et al. [70] treated 40 patients with concurrent rituximab and CHOP, achieving objective remissions in 95% of patients, including 55% CR. No unexpected toxicity was observed as an effect of the combined modality treatment, and the median time to progression was not reached after 50 months of follow-up. In contrast, it is still not possible to fully evaluate the

possible impact of combined immunotherapy with rituximab and interleukin-2 for relapsed or refractory FL patients [71].

To date, the next immunotherapeutic approach in line for delivering clinical answers to clinical questions appears to be radioimmunotherapy, that is the intravenous administration of monoclonal antibodies, mainly still anti-CD20, conjugated with radio-nuclides such as ^{131}I (tositumomab) and ^{90}Y (ibritumomab). For the time being, probably due to a lower side-effect and toxicity intensity, the latter seems capable of outpacing the former, at least in terms of the number and type of trials being conducted and published. The bulk of evidence accumulated in favor of expanding the usage of ibritumomab in FL patients includes: (i) its safe and significant clinical activity in relapsed or refractory FL patients with mild thrombocytopenia [72]; (ii) its capability of inducing significantly better OR and CR rates than rituximab in relapsed or refractory FL patients [73]; and (iii) its effectiveness even in most rituximab-refractory FL patients [74]. On the other hand, in the absence of any comparative study between the two radiolabeled monoclonal antibodies, tositumomab has also shown substantial activity in FL patients, perhaps with a worse toxicity profile [75].

The same Id vaccine therapy that a decade ago showed, for the first time, that it was possible to immunize a cancer patient with an antigen of his own tumor [76] has now entered the arena of phase III clinical trials. Only the two such trials currently ongoing, sponsored by the NCI and Genitope, respectively, will be able to, once and for all, demonstrate whether Id vaccine clinical activity [77, 78] is correlated with better prognosis for previously untreated FL patients [79]. Meanwhile, other phase II clinical trials are also either concluded or ongoing. Among them are that sponsored by the Stanford University, on the possible improvement of the Id vaccine formulation by using Id-pulsed dendritic cells [80], and that sponsored by the University of Navarra, aiming at verifying whether Id vaccine may still be of substantial help for first-relapse FL patients [61].

Finally, despite all this great attention to treatment innovation, the search for a truly FL-suitable, independent prognostic index remains active [4, 81].

Extranodal marginal-zone B-cell lymphoma of MALT-type

The group of mucosa-associated lymphoid tissue (MALT) NHLs comprises a number of low-grade extranodal B-cell lymphomas that share similar clinical, pathological, immunological and molecular features. This condition has been widely accepted only in recent years, and has been included in the REAL/WHO classification as a specific entity, the 'extranodal marginal-zone B-cell lymphoma of MALT-type' (MALT lymphoma) [1, 2].

The origin of MALT lymphoma is an accumulation of auto-reactive lymphoid tissue in mucosa or organs that contains no organized lymphoid tissue [82, 83]. The first required step is the recruitment of B and T lymphocytes into either the mucosa or organs that do not correspond to peripheral sites of the immune system. The acquisition of this organized lymphoid tissue, called MALT, is induced by a series of antigens, and is probably different for each organ.

This particular pathogenesis of MALT lymphoma, with a possible external (environmental or autoimmune) event as the starting point of the disease and with the preferential homing of the neoplastic cells, induces a particular behavior unique among lymphomas, which was described by Isaacson as the MALT concept [84, 85]. Regarding this concept, it is now understood that MALT lymphomas can arise synchronously or metachronously in various distinct extranodal sites, and possibly in multiple MALT and/or non-MALT sites.

Far from being rare, MALT lymphoma accounts for ~7–8% of all NHLs, being the third most frequent histological subtype after DLBCL and FL. The stomach is the most common and best-studied site of involvement [86]. MALT lymphomas have also been described in various non-gastrointestinal sites, such as salivary gland, thyroid, skin, conjunctiva, orbit, larynx, lung, breast, kidney, liver and prostate [87–101].

There are few published studies specifically reporting treatment outcome for MALT lymphoma, and even the more recent among them often refer to retrospective series of RT and CHT, with no significant difference in outcome between patients who received different initial treatments. The OS rates range between 80% and 95% at 5 years, but the PFS is significantly shorter, especially for patients presenting with advanced stage or unfavorable IPI score [102, 103].

For localized gastric MALT lymphoma, there is increasing evidence indicating that antibiotics can be effectively employed as the sole initial treatment: indeed, more than half of the treated patients achieve a histological regression of the gastric lymphoma following eradication of *Helicobacter pylori* [104]. In this context, recent advances in the knowledge of both genetic and molecular features of MALT lymphoma will probably exert a fundamental role in refining the clinical management of the disease. First and foremost, it has been shown that the presence of t(11;18) does correlate with antibiotic resistance [105, 106], progression to a more aggressive tumor and higher potential for local infiltration and distant spread [107–109].

In contrast, no treatment guidelines exist for the management of patients with non-gastric lymphoma, for those with gastric MALT lymphoma who fail antibiotic treatment or for the subset of gastric cases in which no evidence of *H. pylori* can be found. A choice can be made between conventional oncological modalities, including CHT, RT and surgery, each of them alone or in combination. However, Conconi et al. [110] recently reported interesting data on the role of rituximab in gastric MALT lymphoma; therefore, the next reasonable step for *H. pylori*-positive MALT lymphoma is the evaluation of a sequential treatment including antibiotics and rituximab, with the goal of possibly curing most patients.

Conclusion

All in all, it is increasingly evident that lymphoma treatment choice should be as case-tailored as possible, taking into account the site, the stage and both clinical and biological characteristics of the individual patient.

Acknowledgements

This work was supported by grants from FIS Ministerio de Salud – RTIC Cáncer C10/03 (Madrid), Departamento de Educación y Cultura del Gobierno de Navarra (Pamplona), PIUNA (Pamplona), Ruzic Research Foundation (Beverly Shores, IN), A.I.R.C. (Milan), MIUR (Rome) and Fondazione del Monte di Bologna e Ravenna.

References

- Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. *Blood* 1994; 84: 1361–1392.
- Isaacson PG, Muller-Hermelink HK, Piris MA et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Jaffe ES, Harris NL, Stein H et al. (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001; 157–160.
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993; 329: 987–994.
- Solal-Celigny P. Follicular Lymphoma International Prognostic Project (FLIPP). *Ann Oncol* 2002; 13 (Suppl 2): 25.
- Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nat Med* 2002; 8: 13–14.
- Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. *N Engl J Med* 2002; 346: 1937–1947.
- Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N Engl J Med* 2003; 348: 2386–2395.
- Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiation treatment for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. *J Clin Oncol* 2002; 20: 630–37.
- Canellos GP. New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. *J Clin Oncol* 2002; 20: 607–609.
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. *N Engl J Med* 1998; 339: 1506–1514.
- Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. *Ann Oncol* 2002; 13: 75–78.
- Longo DL. Radiation therapy in the treatment of Hodgkin's disease: do you see what I see? *J Natl Cancer Inst* 2003; 95: 928–929.
- Tarella C, Caracciolo D, Corradini P et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated up front with high-dose sequential chemotherapy and autograft. *Leukemia* 2000; 14: 740–747.
- Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. *Blood* 2001; 97: 404–409.
- Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. *Blood* 1996; 88: 2780–2786.
- Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. *Blood* 2002; 99: 75–82.

17. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. *J Clin Oncol* 2000; 18: 3918–3924.
18. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol* 2001; 19: 4238–4244.
19. Sieber M, Tesch H, Pfistner B et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiation treatment in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. *J Clin Oncol* 2002; 20: 476–484.
20. Levis A, Gobbi PG, Chisesi M et al. ABVD vs Stanford V vs MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Results of a randomized trial. *Ann Oncol* 2002; 13 (Suppl 2): 25.
21. Radford JA, Rohatiner AZ, Ryder WD et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. *J Clin Oncol* 2002; 20: 2988–2994.
22. Josting A, Wiedenmann S, Franklin J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2003; 21: 3440–3446.
23. Zinzani PL, Magagnoli M, Bendandi M et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. *Haematologica* 2000; 85: 729–732.
24. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. *Blood* 2001; 98: 2930–2934.
25. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. *Ann Oncol* 2002; 13: 1356–1363.
26. Aleman BM, Raemaekers JM, Tirelli U et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. *N Engl J Med* 2003; 348: 2396–2406.
27. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. *Blood* 2000; 96: 1280–1286.
28. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2002; 20: 221–230.
29. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. *Lancet* 2002; 359: 2065–2071.
30. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 1993; 328: 1002–1006.
31. Miller TP, Dahlberg S, Fisher RI et al. Chemotherapy alone compared with chemotherapy plus radiation treatment for localized intermediate- and high-grade non-Hodgkin's lymphoma. *N Engl J Med* 1998; 339: 21–26.
32. Fillet G, Bonnet G, Mounier N et al. Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin's lymphoma: results of GELA LNH 93-4 study. *Blood* 2002; 100 (Suppl 1): 92a.
33. Miller TP, LeBlanc M, Spier C et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. *Blood* 2001; 98 (Suppl 1): 724a.
34. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2001; 19: 389–397.
35. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; 346: 235–242.
36. Mainwaring PN, Cunningham D, Gregory W et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PADriaCEBO versus PMitCEBO. *Blood* 2001; 97: 2991–2997.
37. Wilder RB, Rodriguez MA, Medeiros LJ et al. International Prognostic Index-based outcomes for diffuse large B-cell lymphomas. *Cancer* 2002; 94: 3083–3088.
38. Wilson WH, Grossbard ML, Pittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. *Blood* 2002; 99: 2685–2693.
39. Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. *Blood* 2002; 2285–2290.
40. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. *Blood* 2002; 99: 815–821.
41. Staudt LM, Wilson WH. Focus on lymphomas. *Cancer Cell* 2002; 2: 363–366.
42. Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. *Am J Med* 2002; 112: 262–268.
43. Haioun C, Itti E, Rahmouni A et al. 18F-fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive non-Hodgkin's lymphoma (NHL): an early prognostic tool for predicting patient outcome. *J Clin Oncol* 2003; 22 (Suppl 1): 2274a.
44. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. *Blood* 2000; 96: 2934–2942.
45. Philip T, Chauvin F, Armitage J et al. PARMA International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. *Blood* 1991; 77: 587–592.
46. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. *Blood* 2002; 96: 2399–2404.
47. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a Groupe d'Etude des Lymphomes de l'Adulte study. *J Clin Oncol* 2000; 18: 3025–3030.
48. Vose JM, Sharp G, Chan WC et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. *J Clin Oncol* 2002; 20: 2344–2352.
49. Ladetto M, Zallio F, Vallet S et al. Concomitant administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. *Leukemia* 2001; 15: 1941–1949.
50. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the

- non-Hodgkin's lymphoma cooperative study group. *J Clin Oncol* 1998; 16: 2796–2802.
51. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. *Blood* 2003; 102: 1989–1996.
 52. Laport GG, Levine BL, Stadtmauer EA et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. *Blood* 2003; 102: 2004–2013.
 53. Howard OM, Gribben JG, Neuberger DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. *J Clin Oncol* 2002; 20: 1288–1294.
 54. Gianni AM, Magni M, Martelli M et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). *Blood* 2003; 102: 749–755.
 55. Romaguera JE, Khouri IF, Kantarjian HM et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. *Leuk Lymphoma* 2000; 39: 77–85.
 56. Romaguera JE, Cabanillas F, Dang NH et al. Mantle cell lymphoma (MCL) – high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-hyperCVAD (R-HCVAD) without stem cell transplant (SCT). *Blood* 2001; 98 (Suppl 1): 3030a.
 57. Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. *Leukemia* 2002; 16: 587–593.
 58. Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. *Blood* 2002; 99: 3158–3162.
 59. Vandenbergh E, Ruiz de Elvira C, Loberiza FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. *Br J Haematol* 2003; 120: 793–800.
 60. Wilson WH, Neelapu S, White T et al. Phase II study of idiotype vaccine following EPOCH-Rituximab treatment in untreated mantle-cell lymphoma. *Ann Oncol* 2002; 13 (Suppl 2): 9.
 61. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. *Expert Rev Anticancer Ther* 2001; 1: 65–72.
 62. Lynch JW, Hei DL, Braylan RC et al. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-Hodgkin's lymphoma. *Am J Clin Oncol* 2002; 25: 391–397.
 63. Hunault-Berger M, Ifrah N, Solal-Celigny P et al. Intensive therapies in follicular non-Hodgkin lymphomas. *Blood* 2002; 100: 1141–1152.
 64. Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. *J Clin Oncol* 2001; 19: 727–735.
 65. Forrest DL, Thompson K, Nevill TJ et al. Allogenic hematopoietic stem cell transplantation for progressive follicular lymphoma. *Bone Marrow Transplant* 2002; 29: 973–978.
 66. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogenic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. *Blood* 2001; 98: 3595–3599.
 67. Hainsworth JD, Burris HA 3rd, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. *Blood* 2000; 95: 3052–3056.
 68. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. *Blood* 2001; 97: 101–106.
 69. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. *Blood* 2002; 99: 856–862.
 70. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. *Semin Oncol* 2002; 29: 36–40.
 71. Friedberg JW, Neuberger D, Gribben JG et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. *Br J Haematol* 2002; 117: 828–834.
 72. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. *Blood* 2002; 99: 4336–4342.
 73. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 2002; 20: 2453–2463.
 74. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol* 2002; 20: 3262–3269.
 75. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. *J Clin Oncol* 2001; 19: 3918–3928.
 76. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. *N Engl J Med* 1992; 327: 1236–1237.
 77. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. *Nat Med* 1999; 5: 1171–1177.
 78. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. *Blood* 1997; 89: 3129–3135.
 79. Timmermann JM. Vaccine therapies for non-Hodgkin's lymphoma. *Curr Treat Options Oncol* 2002; 3: 307–315.
 80. Timmermann JM, Czerwinski DK, Davis TA et al. Idiotype-pulse dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood* 2002; 99: 1517–1526.
 81. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. *Intergruppo Italiano Linfomi*. *Blood* 2000; 95: 783–789.
 82. Isaacson PG, Wright D. Malignant of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. *Cancer* 1983; 52: 1410–1416.
 83. Isaacson PG, Wright D. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. *Cancer* 1984; 53: 2515–2524.
 84. Isaacson PG. Extranodal lymphomas: the MALT concept. *Verh Dtsch Ges Pathol* 1992; 76: 14–23.
 85. Isaacson PG. The MALT lymphoma concept updated. *Ann Oncol* 1995; 6: 319–320.
 86. Zucca E, Bertoni F, Roggero E et al. The gastric marginal zone B-cell lymphoma of MALT type. *Blood* 2000; 96: 410–419.
 87. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. *Hum Pathol* 1988; 19: 1315–1326.

88. Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. *Hum Pathol* 1988; 19: 766–776.
89. Thieblemont C, Bastion Y, Berger F et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: Analysis of 108 patients. *J Clin Oncol* 1997; 15: 1624–1630.
90. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. *Blood* 2000; 95: 802–806.
91. Zinzani PL, Magagnoli M, Galienucci P et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. *J Clin Oncol* 1999; 17: 1254–1258.
92. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. *Ann Oncol* 1997; 8: 727–737.
93. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. *Ann Oncol* 1999; 10: 1023–1033.
94. Kaplan MA, Pettit CL, Zukerberg LR et al. Primary lymphoma of the trachea with morphologic and immunophenotypic characteristics of low-grade B-cell lymphoma mucosa-associated lymphoid tissue. *Am J Surg Pathol* 1992; 16: 71–75.
95. Nicholson AG, Wotherspoon AC, Diss TC et al. Pulmonary B-cell non-Hodgkin's lymphomas: the value of immunohistochemistry and gene analysis in diagnosis. *Histopathology* 1995; 26: 395–403.
96. Isaacson PG, Chan JKC, Tang C et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus: a thymic lymphoma mimicking myoepithelial sialadenitis. *Am J Surg Pathol* 1990; 14: 342–351.
97. Mattia AR, Ferry JA, Harris NL. Breast lymphoma: a B-cell spectrum including the low-grade B-cell lymphoma of mucosa associated lymphoid tissue. *Am J Surg Pathol* 1993; 17: 574–587.
98. Bailey EM, Ferry JA, Harris NL et al. Marginal zone lymphoma (low grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue. *Am J Surg Pathol* 1996; 20: 1011–1023.
99. Isaacson PG, Banks PM, Best PV et al. Primary low-grade hepatic B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)-type. *Am J Surg Pathol* 1995; 19: 571–575.
100. Wotherspoon AC, Hardman-Lea S, Isaacson PG. Mucosa-associated lymphoid tissue (MALT) in the human conjunctiva. *J Pathol* 1994; 174: 33–37.
101. Parveen T, Navarro-Roman L, Medeiros LJ et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the kidney. *Arch Pathol Lab Med* 1993; 117: 780–783.
102. Cavalli F, Isaacson PG, Gascoyne RD et al. Malt lymphomas. *Hematology (Am Soc Hematol Educ Program)* 2001; 241–258.
103. Hitchcock S, Ng AK, Fisher DC et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 2002; 52: 1058–1066.
104. Bayerdorffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of *Helicobacter pylori* infection. MALT Lymphoma Study Group. *Lancet* 1995; 345: 1591–1594.
105. Liu H, Ruskon-Fourmestreaux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to *Helicobacter pylori* eradication therapy. *Lancet* 2001; 357: 39–40.
106. Liu H, Ye H, Ruskon-Fourmestreaux A et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to *H. pylori* eradication. *Gastroenterology* 2002; 122: 1286–1294.
107. Liu H, Ye H, Dogan A et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. *Blood* 2001; 98: 1182–1187.
108. Starostik P, Patzner J, Greiner A et al. Gastric marginal zone B-cell lymphomas of MALT type develop along two distinct pathogenetic pathways. *Blood* 2002; 99: 3–9.
109. Remstein ED, Kurtin PJ, James CD et al. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. *Am J Pathol* 2002; 161: 63–71.
110. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. *Blood* 2003; 102: 2741–2745.